Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vormatrigine in adults with focal seizures
2025-524038-24-00Phase 3Completed
- Sponsor
- Praxis Precision Medicines
- Start
- May 2026
- Modality
- Classical Binding Small Molecules → Small Molecules
- Countries
- 7
01
Overview
Phase 3, randomised, double-blind trial of vormatrigine in Focal Onset Epilepsy (4 arms), sponsored by Praxis Precision Medicines. Primary endpoint: 50% responder rate. Started May 2026; status: completed.
02
Drugs
vormatrigine
03
Conditions
Focal Onset Epilepsy
Beyond the preview
Go deeper on 2025-524038-24-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-524038-24-00.